2024
Systemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis.
Adelson K, Canavan M, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Cheng L. Systemic anti-cancer treatment and healthcare utilization at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 20: 276-276. DOI: 10.1200/op.2024.20.10_suppl.276.Peer-Reviewed Original ResearchEnd-of-lifeSystemic anticancer therapyDay of deathIntensive care unit useIntensive care unitHealthcare utilizationEmergency departmentCombined chemo-immunotherapyEnd-of-life chemotherapy useAssociated with healthcare utilizationImmunotherapy useChemo-immunotherapyIncreased healthcare useEnd of lifeAdverse quality of lifeAssociated with higher EDCare unitQuality of lifeSystemic anti-cancer treatmentHospice useDay hospiceHospice enrollmentSEER-Medicare databaseUse of chemotherapyHealthcare useSystemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncology 2024, 10: 887-895. PMID: 38753341, PMCID: PMC11099840, DOI: 10.1001/jamaoncol.2024.1129.Peer-Reviewed Original ResearchNational Quality ForumQuintile 5Quintile 1Improve end-of-life careEnd-of-life careCohort studyNationwide population-based cohort studyPopulation-based cohort studyEnd of lifeElectronic health record databaseHealth care practicesColorectal cancerPopulation of patientsCox proportional hazards modelsAmerican Society of Clinical OncologyQuality ForumCare practicesOverall survivalPayment incentivesProportional hazards modelHighest quintileMultivariate Cox proportional hazards modelQuintileFlatiron HealthHazard ratioSystemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.
Adelson K, Cheng L, Huang Y, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Canavan M. Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 42: 11092-11092. DOI: 10.1200/jco.2024.42.16_suppl.11092.Peer-Reviewed Original ResearchSystemic anticancer therapyCombined chemo-immunotherapyLiquid tumorsSolid tumorsDay of deathEmergency departmentRates of systemic therapySystemic anti-cancer therapySEER-Medicare databaseAnti-cancer therapyChemo-immunotherapyLT patientsSystemic therapyCI patientsSEER-MedicareST patientsIdentified patientsCost of drugsAssociated with higher costsEnd of lifeAnticancer therapyImmunotherapyChemotherapyPatientsTherapy
2023
End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting. Journal Of Clinical Oncology 2023, 41: 4729-4738. PMID: 37339389, PMCID: PMC10602547, DOI: 10.1200/jco.22.02180.Peer-Reviewed Original ResearchConceptsSystemic treatmentEnd of lifeWhite patientsBlack patientsOdds ratioLarge real-world populationPractice settingsTreatment ratesPatient-level factorsEmergency department useIntensive care unitReal-world populationDay of deathImmunotherapy eraSystemic therapyOncologic treatmentCare unitDeidentified databaseDepartment usePatient raceInsurance typeMetastatic cancerDownstream careMedicaid patientsHigher oddsThe association between systemic anticancer therapy (SACT) at the end of life (EOL) and acute care use among patients treated at oncology practices participating in the Oncology Care Model (OCM).
Canavan M, Sheth K, Scott J, Westvold S, Adelson K. The association between systemic anticancer therapy (SACT) at the end of life (EOL) and acute care use among patients treated at oncology practices participating in the Oncology Care Model (OCM). Journal Of Clinical Oncology 2023, 41: 6580-6580. DOI: 10.1200/jco.2023.41.16_suppl.6580.Peer-Reviewed Original ResearchSystemic anticancer therapyDay of deathOncology Care ModelEnd of lifeAcute care useIntensive care unitInpatient admissionsED visitsCare useReceipt of chemotherapyAcute care utilizationEmergency department useProportion of decedentsRates of chemotherapyChi-square testICU stayIO therapyCare unitCare utilizationInpatient stayCT patientsDepartment useHospice useCare metricsOncology practiceThe impact of receipt of systemic anticancer therapy (SACT) near the end of life (EOL) on cost among oncology practices participating in CMS' Oncology Care Model (OCM).
Adelson K, Canavan M, Sheth K, Scott J, Westvold S. The impact of receipt of systemic anticancer therapy (SACT) near the end of life (EOL) on cost among oncology practices participating in CMS' Oncology Care Model (OCM). Journal Of Clinical Oncology 2023, 41: e18923-e18923. DOI: 10.1200/jco.2023.41.16_suppl.e18923.Peer-Reviewed Original ResearchSystemic anticancer therapyDay of deathOncology Care ModelEnd of lifeAcute care useSystemic therapyCT patientsCare useImpact of receiptMean episode costReceipt of chemotherapyReceipt of immunotherapyICU useED costsIO patientsPharmacy costsOncology practiceEpisode costsTreatment decisionsDownstream careCare modelAmbulatory settingPart BPatientsImmunotherapy